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Object: The treatment of choice in glioblastoma (GBM) is the maximal surgical
extent of resection (EOR) followed by adjuvant chemo-radiotherapy. Furthermore,
methylguanine-DNA methyltransferase (MGMT) promoter methylation is associated with
prolonged overall survival (OS) and progression free survival (PFS). The objective of the
present study is correlate the biomolecular aspects in relation with EOR.
Materials and methods: We analyzed a series of 116 patients with IDH-1 wild type
GBM and different EOR (Gross Total Resection—GTR-, Partial Resection—PR- and
Biopsy), treated with adjuvant chemo-radiotherapy. The MGMT status was analyzed in
terms of promoter methylation and protein expression.
Results: When GTR was possible, OS and PFS were significantly better compared to
the other two groups (p = 0.001 and p = 0.035, respectively). MGMT methylation was
significantly associated with better OS in the biopsy group (p= 0.022) and better OS and
PFS in PR (p = 0.02 and p = 0.012, respectively), but not in the GTR group (p = 0.252
for OS, p = 0.256 for PFS) nor the PFS in the biopsy group (p = 0.259). MGMT protein
expression levels do not show any association with OS and PFS, regardless of the type
of surgery.
Conclusions: Our study confirms the positive association of a safe maximal EOR with
better OS and PFS, and indicates a positive prognostic value of MGMTmethylation status
only in case of the presence of residual tumor tissue. MGMT protein expression seems
not to play a clinical role in relation with the type of surgery.
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INTRODUCTION
Glioblastoma (GBM) is the most common primary malignant
brain tumor in adults (1). Currently, safe optimal surgical
resection followed by adjuvant radiotherapy and chemotherapy
is considered as the standard treatment approach for patients
with GBM (2–4). However, despite advances in the last three
decades and aggressive multimodal treatment, outcome remains
poor for patients with GBM, with a median overall survival of
14–17 months from time at diagnosis (2, 3). Many studies have
reported a positive correlation between the extent of resection
(EOR) and the overall survival (OS) in patients with GBM, in
particular for patients undergoing Gross Total Resection (GTR)
with respect to whom receiving only a Subtotal Tumor Resection
(STR) (5).
When GTR is not possible (due to several causes such as
disease location and extension, general conditions of the patient),
no clearly recognized criteria are proposed in the literature
in order to stratify the STR group and, as a consequence,
the threshold of EOR required for better prognosis remains
controversial. Moreover, a recent observational retrospective
study (6) has enrolled 38 patients who underwent PR and 78
biopsies and has pointed out that PR failed to improve OS and
PFS compared with biopsy in patients with GBM (p = 0.84 and
0.48, respectively). Even the propensity score matching (PSM)
between the PR and biopsy groups, according with this study,
did not show any significant difference in OS and PFS between
the groups (p = 0.51 and 0.75, respectively). The hazard ratios
for OS and PFS of PR compared with biopsy were 0.98 and
0.73, respectively; however, the difference was not statistically
significant (p = 0.96 and 0.39, respectively). Moreover, the
surgical complication rate was higher in the PR group (14/32,
43.7%) than in the biopsy group (9/78, 11.5%) (p < 0.01). The
cited study confirms that no significant association and benefit
has been clearly yet demonstrated between the different degrees
of PR and the biomolecular markers in regards of OS and PFS.
Methylguanine-DNA methyltransferase (MGMT) plays
the pivotal role in the management of GBM patients:
hypermethylation of MGMT promoter (causing absence
of MGMT protein expression) leads to a higher response
to temozolomide (TMZ), thus improving the patients’
outcome (2, 7, 8). Furthermore, it has been discovered that
additional mechanisms may decrease the MGMT expression.
Approximately 20% of all patients with unmethylated
GBM experiences an unexpected favorable outcome after
chemoradiation, because mRNA expression was found to be
unexpectedly low (9–11).
Only a few studies have investigated the influence of surgery
on the clinical outcome in regards of the molecular markers
(4, 12). Gessler et al. in their recent publication confirm that GTR
is able to prolong PFS and OS when compared to incomplete
Abbreviations: EOR, Extent of Resection; GBM, Glioblastoma; GTR, Gross
Total Resection; IDH, Isocitrate Dehydrogenase; IHC, immunohistochemistry;
MGMT, methylguanine-DNA methyltransferase; PFS, Progression Free
Survival; PR, Partial Resection; OS, Overall Survival; STR, Subtotal Resection;
TMZ, temozolomide.
resection, and the presence of methylation is a prognostic factor
increasing significantly PFS and OS (4).
The aim of this study is to assess the relation between
EOR and MGMT status (in terms of MGMT deregulation
methylation and protein expression) by analyzing the clinical
outcome (PFS and OS) of radio-chemotherapy treated IDH-
1 wild type GBM patients, in correlation with the type
of surgery.
MATERIALS AND METHODS
This bi-center retrospective cohort study included patients with
newly diagnosed histologically reviewed GBM with IDH-1 wild
type status from 2004 until 2013.
This work has been conducted in compliance with the
protocol, the current version of the Declaration of Helsinki, the
ICH-GCP or ISO EN 14155 (as far as applicable) as well as all
national legal and regulatory requirements. Data and samples
have been collected and analyzed for the study purpose only
after the required authorizations from the competent Ethics
Committees were obtained (Rif. CE 3086-2016-01108).
Inclusion criteria consist of age >18 years, histological
diagnosis of IDH-1 wild type GBM (WHO IV), therapy with
TMZ according with the Stupp scheme (60 Gray radiotherapy
and concomitant chemotherapy with TMZ, followed by six cycles
of maintenance TMZ), death caused by GBM, tissue availability
for biomolecular analyses.
The OS (defined as the time from surgery to the date of death)
and PFS (defined as the time from the first radio-chemotherapy
treatment to the date of clinical or radiological progression
according with the RANO criteria) were analyzed. Regarding
the type of surgery, three groups were defined according with
the post-op MRI performed in the first 72 h: GTR (with no
contrast-enhancing residual tissue visible on T1 injected MRI
sequences), incomplete Partial Resection (PR) (with evidence of
contrast-enhancing residual tumor) and Biopsy.
Molecular Analyses
MGMT Promoter Methylation
Tissues for genomic DNA isolation were dissectedmanually from
three 8-µm sections and DNA was obtained using automatic
extraction (Maxwell, Promega, Madison, WI, USA). About
50–100 ng of DNA were subjected to bisulphite treatment
using EZ DNA Methylation-Gold TM kit (Zymo Research,
Irvine, CA, USA). Methylation status of six consecutive
cytosines of MGMT promoter (chr10:131,265,507−131,265,556)
was assessed by PCR-pyrosequencing of bisulphite-treated DNA
by usingMGMTPlus kit according to the recommended protocol
(Diatech Pharmacogenetics, Jesi, Italy). A cut-off of 10% was
set to score presence of promoter methylation. This value was
determined calculating the limit of negative controls (DNA
samples from 15 FFPE healthy brain tissues) for each cytosine
(mean of methylation ratio adding 2× the Standard Deviation)
assuming a Gaussian distribution of the raw signal from negative
samples. The limit corresponded to 95% of the observed
negative values.
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MGMT Immunohistochemistry
Immunohistochemical reactions for MGMT protein were
performed on whole tissue sections obtained from formalin-
fixed, paraffin-embedded (FFPE) tumor blocks. Three -µm-thick
sections were deparaffinized, rehydrated and pretreated with
citrate buffer pH6 in microwave oven for 20min. Monoclonal
primary antibody anti-MGMT, clone MT3.1 (Chemicon
International, Temecula, CA, USA) was used at a dilution of
1/400 and applied overnight at 4◦C, followed by a polymeric
detection system (Ultravision DAB Detection System, LabVision,
Fremont, CA, USA) according to the manufacturer’s protocol.
According to the literature, immunohistochemical positivity was
scored when more than 5% of neoplastic cells showed an intense
nuclear staining (13, 14).
Statistical Analyses
Mean and median values were calculated at first to summarize
results of each variable. The relative chi-square values were
calculated on pairs of variables to describe the statistical
association existing among variables: null hypothesis stating the
lack of marginal association between pairs of variables (after
discretization) was assessed through the chi-square test.
OS and PFS curves for censored data were obtained using the
Kaplan-Meier estimator; comparisons of curves given different
molecular characterizations were performed by logrank tests. PFS
curves were also estimated and tested within strata defined by the
variable of surgery.
All the analyses, graphs and reports were performed using the
R software [R] and the following R packages: survival, bootstrap,
rmarkdown, knitr (15–18).
RESULTS
The study includes 116 patients, 57 females (49.1%) and 59 males
(50.9%). Among them, 81 underwent GTR of the tumor (69.8%),
18 PR (15.5%) while in 17 cases only biopsy was performed
(14.7%). In 92 patients (corresponding to 79.3% of the whole
cohort), we observed progression of the disease (PD), while the
remaining 24 cases (20.7%) include both the six patients who are
still alive (N = 6) and the 18 patients who deceased for other
causes with no evidence of tumor progression.
Concerning the biomolecular aspects, 71 samples showed
absence of MGMT promoter methylation tumors (61.2%), 41
methylation (35.3%) while in four samples the methylation status
was not evaluable (3.4%). The immunohistochemical evaluation
of the MGMT protein revealed a positive expression in 54
samples (46.5%) and a negative expression in 44 cases (37.9%),
while in 18 cases (15.5%) the assay did not give evaluable results
(Table 1). As for clinical data, OS was 15.5 months and PFS was
7 months.
We then analyzed the correlation between the type of surgery
and the OS (Figures 1A,B). Patients who underwent a GTR
had a significantly better OS (17 months) compared with those
in whom a PR (14 months) or a biopsy (9 months) had
been performed (Log-rank p = 0.001; GTR: HR = 0.3521,
95%CI: 0.1989, 0.6235; PR: HR= 0.3926, 95%CI: 0.1908, 0.8075)
(Figure 1A). Analogously, grouping the patients who sustained
TABLE 1 | Synoptic overview of the patient population.
Patients 116
IDH1 wild type GBM WHO IV 116
Female 57 49.1%
Male 59 50.9%
GTR 81 69.8%
PR 18 15.5%
Biopsy 17 14.7%
Surgery + Radio-chemotherapy 116
Deceased 110 94.8%
Alive 6 5.1%
Progression Disease (PD) 92 79.3%
Alive with no evidence of PD 6 5.1%
Deceased with no evidence of PD 18 15.5%
MGMT methylated 41 35.3%
MGMT non-methylated 71 61.2%
MGMT non definable 4 3.4%
MGMT protein expression positive 54 46.5%
MGMT protein expression negative 44 37.9%
MGMT expression not evaluable 18 15.5%
GBM, Glioblastoma; GTR, Gross Total Resection; MGMT, methylguanine-DNA
methyltransferase; PR, Partial Resection.
PR and biopsy, we confirmed a significant longer OS for patients
subjected to GTR (GTR = 17 months, PR + Biopsy = 11.5
months, Log-rank p= 0.0333; GTR: HR= 1.571, 95%CI: 1.0316,
2.3923) (Figure 1B). Similar results were obtained by comparing
the type of surgery and PFS (Figures 1C,D). Indeed, the GTR
group presented a longer PFS compared with the PR group and
the biopsy group (GTR = 8.25 months, PR = 7.50 months,
Biopsy= 4.00 months, Log-rank p= 0.0352; GTR: HR= 0.3681,
95%CI: 0.1738, 0.7799; PR: HR= 0.4444, 95%CI: 0.1877, 1.0522)
(Figure 1C). On the contrary, GTR did not give a significant
greater PFS compared with the value of the other two groups
considered together (GTR = 8.25 months, PR + Biopsy = 7.00,
Log-rank p= 0.1187; PR+ biopsy: HR= 1.4774, 95%CI: 0.9211,
2.3698) (Figure 1D).
Afterwards, the OS and the PFS were analyzed in relation with
the MGMT promoter methylation and the protein expression
evaluated by immunohistochemistry (IHC) (Figures 2A–D).
The OS is significantly better in MGMT methylated GBMs
than in MGMT unmethylathed ones (methylated: 19.5 months,
unmethylathed: 14 months, Log-rank p = 0.0056; U: HR
= 1.7653, 95%CI: 1.174, 2.6544) (Figure 2A). Same positive
correlation, statistically significant, was found for PFS, with 9
months before progression in MGMT methylated patients and
7 months for MGMT unmethylated ones (Log-rank p = 0.0347;
U: HR= 1.6014, 95%CI: 1.037, 2.473) (Figure 2B).
Regarding the levels of MGMT protein expression, patients
who had low MGMT protein expression had a significantly
improved OS compared with patients who had high MGMT
protein expression (18 vs. 13 months; Log-rank p = 0.0148;
Pos: HR = 1.6929, 95%CI: 1.1165, 2.567) (Figure 2C). On the
contrary, no significant correlation was observed for MGMT
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FIGURE 1 | Overall survival for each type of surgery (A) and grouping PR and biopsy groups (B). Progression free survival for each type of surgery (C) and grouping
PR and biopsy groups (D). C.I., Confidence interval; GTR, gross total resection; H.R., hazard ratio; PR, partial resection.
protein expression in regards of PFS (8.75 months for GBMs
showing low protein expression and 7 months for those with
high protein expression, Log-rank p= 0.3166; Pos: HR= 1.2486,
95%CI: 0.8013, 1.9458) (Figure 2D).
Furthermore, we analyzed the outcome (in terms of both
OS and PFS) subdividing the cohort on the basis of the three
different types of surgery, in relation with the methylation status
of the MGMT gene (Figures 3A–F). No significant correlation
was found in patients with GTR between OS and methylation
status (methylated = 19 months, unmethylated = 16 months,
Log-rank p = 0.252; U: HR = 1.3125, 95%CI: 0.8277, 2.0813)
(Figure 3A). A positive correlation was shown, instead, in the
PR group, in which MGMT methylated patients had a better
OS compared with the unmethylated ones (methylated = 31.8
months, unmethylated = 13.0 months, Log-rank p = 0.0205;
U: HR = 8.5176, 95%CI: 1.0472, 69.2787) (Figure 3B). The
same positive statistically significant correlation was observed
in patients who underwent biopsy (methylated = 21 months,
unmethylated = 9 months, Log-rank p = 0.0226; U: HR =
undefined, 95%CI: 0,∞) (Figure 3C).
As regards the PFS, patients who underwent a GTR and were
MGMT methylated did not show a better outcome if compared
with patients carrying MGMT unmethylated GBM (methylated
= 9 months, unmethylated = 7 months, Log-rank p = 0.256;
U: HR = 1.3215, 95%CI: 0.8134, 2.147) (Figure 3D). On the
contrary, a statistically significant better PFSwas noted inMGMT
methylated patient with respect to MGMT unmethylated ones
in the PR group (methylated = 13 months, unmethylated = 7
months, Log-rank p = 0.0117; U: HR = 9.0791, 95%CI: 1.141,
72.2475) (Figure 3E). Finally, absence of correlation between PFS
and the methylation status was observed in the group of patients
who underwent a biopsy (methylated= 5 months, unmethylated
= 3 months, Log-rank p = 0.2982; U: HR = 2.5982, 95%CI:
0.2975, 22.6896) (Figure 3F).
Moreover, we analyzed the same variables (clinical outcome
and EOR) on the light of the results of MGMT protein
expression (Figures 4A–F). In terms of OS, patients who
underwent a GTR with a low protein expression had a significant
better outcome with respect to patients with high MGMT
expression (low protein expression = 19.8 months, high protein
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FIGURE 2 | Overall survival (A) and progression free survival (B) according with the MGMT methylation status. Overall survival (C) and progression free survival (D)
according with the immunohistochemistry results. C.I., Confidence interval; H.R., hazard ratio; M, methylated; neg, IHC negative; pos, IHC positive; U, unmethylated.
expression = 16.5 months, Log-rank p = 0.0476; Pos: HR =
1.6592, 95%CI: 1.0144, 2.714) (Figure 4A). On the contrary, no
significant correlations were found in the PR and in the biopsy
groups regarding MGMT protein expression in terms of OS: 17
months for low protein expression patients vs. 12.5 months for
those with high protein expression in the PR group (Log-rank p
= 0.3702; Pos: HR= 1.6552, 95%CI: 0.5554, 4.9325) (Figure 4B),
and 11 months in low protein expression patients vs. 8 months
in patients with high MGMT expression in the biopsy group
(Log-rank p = 0.42; Pos: HR = 1.596, 95%CI: 0.4772, 5.3374)
(Figure 4C).
As regards PFS, IHC showed no significant relation between
low and high protein expression patients in any group. In the
GTR patients, the difference in PFS between low expressed and
high expressed cases was 9.5 vs. 8 months (Log-rank p = 0.6387;
Pos: HR = 1.1313, 95%CI: 0.6718, 1.905) (Figure 4D). In the PR
group, PFS was 10 months for low protein expression patients
vs. 7 months for patients with high MGMT protein levels (Log-
rank p = 0.3034; Pos: HR = 1.8299, 95%CI: 0.5637, 5.9407)
(Figure 4E). In the biopsy group, patients showing low protein
expression level had a PFS of 5 months compared with 3 months
of those with a high MGMT protein expression (Log-rank p =
0.259; Pos: HR= 2.3493, 95%CI: 0.3908, 14.1236) (Figure 4F).
DISCUSSION
Our paper presents a bicentric, retrospective study including a
series of patients affected by IDH-1 wild type GBM treated with
chemotherapy and radiotherapy after surgery.
Firstly, compared to the data in the literature, we tried to
define three new unambiguous categories of surgical treatment:
GTR, when no evidence of residual tumor on the T1 injected
post-op sequences MRI; PR, if any enhancement is visible
(independently of the residual volume); and biopsy, if only a
small piece of tumor is taken for analysis. We think that this
categorization is a novelty in literature considering the PR as the
presence of residual tumor, regardless its volume. All the other
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FIGURE 3 | Overall survival according with the MGMT methylation status for the gross total resection group (A), the partial resection group (B), and the biopsy group
(C). Progression free survival according with the MGMT methylation status for the gross total resection group (D), the partial resection group (E), and the biopsy group
(F). C.I., Confidence interval; H.R., hazard ratio; M, methylated; U, unmethylated.
studies, in fact, have defined the residual volume in a percentage
that, in the majority of cases, may be subjective.
Our results confirm the well established statement for which,
when feasible, GTR is the gold standard to achieve in the surgical
treatment of GBMs with a longer term OS in this group of
patients vs. both the PR group and the biopsy group (17 vs.
14 vs. 9 months for the different groups, respectively). Similar
data are obtained comparing the GTR group with the PR +
biopsy combined one (17 vs. 11.5, respectively). However, as
stated above, the GTR in our work is the complete absence of
residual tumor on the postop MRI and not, as in literature, the
variable majority of tumor resected (>95 or >97%) considering
the difficulty in the objective calculation of the percentage of the
remnant tumor.
Regarding the PFS, we observed the same significant positive
relation in favor of the GTR group compared with the PR and
biopsy groups taken singularly (8.25 vs. 7.5 vs. 4, respectively)
but not when the latter two (PR + biopsy) are assembled
together. Also these data confirm the already published ones but,
differently, in our work, the PR is considered any enhancement
of any size visible on the postoperative MRI.
In respect of the MGMT methylated status and the better
outcome, our results are in line with the main series published in
literature (7, 19) with a median OS of 19.5 months for patients
with a MGMT methylated GBM vs. 14 months for patients
with an MGMT unmethylated GBM and 2 months more of PFS
between the two groups. However, while the better prognosis in
terms of OS was confirmed by protein expression levels assessed
by IHC, no significant correlation between the two groups (low
and highMGMT protein expression) was shown for the PFS with
this analysis. Therefore, our study confirms the lower diagnostic
value of IHC as compared to the evaluation of the MGMT
methylation status.
The most interesting results have been obtained matching
the MGMT status and the EOR. While we observed that the
MGMT status is positively and significantly correlated to the
clinical outcome in the PR group (OS of 31.8 months for
patients with MGMT methylated GBM with respect to only 13
months for MGMT unmethylated GBM, PFS of 13 vs. 7 months,
respectively), in the group of patients who underwent a GTR
we did not observe any significant association between OS or
PFS and the methylation status of MGMT gene. Likewise, the
simple biopsy did not change significantly the outcome in terms
of PFS in methylated vs. unmethylated patients with only 2
months achieved before disease progression. However, in terms
of OS, patients characterized by an MGMT methylated GBM
have an advantage of 12 months with respect to patients with an
MGMT unmethylated tumor. Our results confirm those recently
published but using clearly, objective and widely applicable
categories of EOR (4, 12). Therefore, we can postulate that
the identification of MGMT promoter methylation may identify
a group of GBM patients who are correlated with a better
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FIGURE 4 | Overall survival according with the protein expression in immunohistochemistry for the gross total resection group (A), the partial resection group (B), and
the biopsy group (C). Progression free survival according with the protein expression in immunohistochemistry for the gross total resection group (D), the partial
resection group (E), and the biopsy group (F). C.I., Confidence interval; H.R., hazard ratio; neg, IHC negative; pos, IHC positive.
response to the combined chemo-radiotherapy treatment only
if the neoplastic tissue is still present. On the contrary, patients
who are bona fide radically resected, will experience the same
follow-upwith respect to the combined chemo-radiation therapy.
IHC represents the classic worldwide used method for the
detection of protein expression. However, especially for MGMT
protein (as for other proteins located in cell nucleus), it can
be sometimes hard to be evaluated, leading to the conclusion
that MGMT promoter methylation should be the preferred
method for assessing MGMT deregulation instead of IHC. In
fact, literature reports that sometimes there is no correlation
between MGMT expression and its promoter methylation (20).
Also in our series IHC does not confirm the expected significant
correlation between low protein expression and better clinical
outcome in PR and biopsy groups. Indeed, the only favorable
significant correlation (borderline, p= 0.047) for the low protein
expression was noted in the OS for the patients who underwent
GTR: they presented almost 20 months of survival vs. 16.5
months of those with samples expressing high levels of MGMT
protein. Neither the GTR nor the PR or the biopsy group showed
a significant relation between IHC and PFS.
Beside IHC limits, also the definition of MGMT promoter
methylation is sometimes challenging, however literature reports
some cut-off values that can be used to define a sample as positive
for MGMT methylation (21). In our work we applied a cut-
off of 10% that was decided on the bases of an internal control
evaluation of a cohort of negative (healthy tissues) samples.
Our study present some limitations, such as the number of
patients included in the analysis is small if compared to other
series, even if not inferior to the majority of studies published.
For this reason, the results of the present work are in line with
those in the literature and seem to be not innovative. However,
several aspects are not exhaustively treated in literature and some
features can be helpful in everyday practice as, for example, the
simple classification between GTR and PR or the importance
of radio-chemotherapy in case of residual enhancement on the
postoperative images.
To conclude, the present study confirms the better outcome
in patients with GBM who sustained a GTR: maximal EOR in
surgery seems to be confirmed as the most important prognostic
value for OS and PFS in the treatment of GBM patients, thus
indicating that, whenever possible, this is the goal that must be
pursued by clinicians. Under these conditions, the most relevant
biomarker, MGMT, does not seem to play any prognostic role.
Theoretically and provocatively, the present study states that
chemo-radiotherapy, in presence of complete resection, could
not influence significantly OS and PFS, playing a substantial role
only in case of residual tumor. When surgery is not possible, the
MGMT methylated status is proven to be a favorable marker for
OS and PFS in patients with remnant tumor after an incomplete
tumor resection (in both PR and biopsied patients). On the
contrary, IHC expression does not correlate with different OS
or PFS in relation with the type of surgery, thus confirming the
discrepancy between protein expression andMGMTmethylation
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status evaluation and suggesting a superior predictive role of
the latter.
We think that the current study, to the best of our knowledge,
is one of the few studies which correlates biological aspects
and different type of surgery in GBM patients treated with
a combined chemo-radiotherapy. However, considering the
continuous changes in the field of brain tumors, further studies
are needed in order to confirm our data and to identify other
possible correlations between the newest biological markers,
the clinical outcome and the surgical treatment in patients
with GBM.
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